The Sierra Leone Telegraph: 1 March 2012
In preparation of the conference “Healthcare In Africa”, taking place in Cape Town on March 6 & 7, the Economist Intelligence Unit (EIU), has published its report: “The Future Of Healthcare In Africa”, commissioned by Janssen Pharmaceutica NV.
The report focuses on five possible future scenarios for African healthcare systems over the next ten years.
Thirty-four leading healthcare experts, representing the entire chain of stakeholders across the sector, helped the editors identify the key trends shaping African healthcare systems.
Jane Griffiths, Company Group Chairman of Janssen in EMEA, explains : “The study draws a very high level picture, combining statistics with trends and possible scenarios that could form the basis for further discussions on which policy options to take. Solutions can only become clearer by having open and constructive discussions with all parties involved, based on factual analyses”.
Janssen is active in Africa in many ways. Apart from selling its products across the region, the company has also set up a number of projects specifically designed for infectious and neglected diseases, including research for a new tuberculosis treatment in collaboration with the TB Alliance, a microbicide targeting HIV, with the International Partnership for Microbicides, a new research programme against elephantiasis and river blindness with the Drugs for Neglected Diseases initiative (DNDi) and the Gates Foundation, as well as against sleeping sickness, Chagas and visceral leishmaniasis.
For the products that are already approved, Janssen sets up access programmes, such as the recently concluded agreements with generic manufacturers in Africa to distribute the company’s HIV/AIDS compounds, or the free distribution of treatments against intestinal infections with the Children Without Worms programme.
About the report
The report “The Future Of Healthcare In Africa” can be downloaded as a free pdf document from: http://www.janssen-emea.com/future-of-healthcare-africa
The Janssen Pharmaceutical Companies of Johnson & Johnson are dedicated to addressing and solving the most important unmet medical needs of our time, including oncology, immunology, neuroscience, infectious disease, and cardiovascular and metabolic diseases.
Driven by our commitment to patients, we develop innovative products, services and healthcare solutions to help people throughout the world.
More information can be found at http://www.janssen-emea.com
Read the Backgrounder on Janssen in Africa: http://www.janssen-emea.com/sites/default/files/Backgrounder%20Janssen%20in%20Africa.pdf
For further information contact: Stefan Gijssels, Vice President Communications & Public Affairs : +32 473 710 425 or email@example.com